Advaxis Inc. (ADXS) Trading 11.3% Higher
Advaxis Inc. (NASDAQ:ADXS)’s share price traded up 11.3% during trading on Monday . The company traded as high as $16.05 and last traded at $15.87, with a volume of 2,160,888 shares traded. The stock had previously closed at $14.26.
A number of equities analysts have commented on the stock. Jefferies Group reaffirmed a “buy” rating on shares of Advaxis in a research report on Friday, June 10th. Barclays PLC lifted their target price on Advaxis from $15.00 to $20.00 and gave the stock an “overweight” rating in a report on Wednesday, August 3rd. HC Wainwright reissued a “buy” rating and set a $23.00 target price on shares of Advaxis in a report on Friday, August 5th. Finally, FBR & Co reissued an “outperform” rating and set a $34.00 target price on shares of Advaxis in a report on Thursday, July 7th. Six investment analysts have rated the stock with a buy rating, The stock has a consensus rating of “Buy” and an average target price of $25.80.
The company’s market capitalization is $547.41 million. The company’s 50-day moving average price is $9.13 and its 200-day moving average price is $8.27.
In related news, Director Thomas J. Mckearn sold 4,100 shares of the stock in a transaction on Friday, May 13th. The stock was sold at an average price of $7.45, for a total value of $30,545.00. Following the completion of the sale, the director now directly owns 82,120 shares of the company’s stock, valued at approximately $611,794. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.
Advaxis, Inc is a clinical-stage biotechnology company. The Company’s immunotherapies are based on a platform technology that utilizes live attenuated Listeria monocytogenes (Lm or Listeria) bioengineered to secrete antigen/adjuvant fusion proteins. It is focused on the discovery, development and commercialization of Lm-LLO cancer immunotherapies.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.